Francesca Tribuzio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francesca Tribuzio has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Antonietta Rosa Silini
Centro di Ricerca E. Menni, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy
1 shared publication - Costanza Bertani
Laboratory of Traumatic Brain Injury and Neuroprotection Department of Acute Brain and Cardiovascular Injury Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan Italy
1 shared publication - Cristina Banfi
Unit of Functional Proteomics, Metabolomics and Network Analysis, Centro Cardiologico Monzino IRCCS, 20138 Milan, Italy
1 shared publication - Edoardo Mazzone
Laboratory of Traumatic Brain Injury and Neuroprotection Department of Acute Brain and Cardiovascular Injury Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan Italy
1 shared publication - Edoardo Micotti
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
1 shared publication - Elisa Roncati Zanier
Department of Acute Brain and Cardiovascular Injury, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
1 shared publication
Latest Publications
- Open Access
- 19 June 2025
- Published by Wiley in Advanced Science
- Vol. 12 (29) , e15508
Mesenchymal Stromal Cell Secretome and Its Key Bioactive Metabolites Induce Long‐Term Neuroprotection After Traumatic Brain Injury in Mice
The severe and long‐term consequences of traumatic brain injury (TBI) highlight the urgent need for effective neuroprotective therapies. Mesenchymal stromal cells (MSCs) show promise in TBI treatment through their secretome (conditioned media, CM). A low‐molecular‐weight (<700 Da) CM fraction with neuroprotective effects comparable to total CM after acute brain injury in vitro is previously identified. Here, it is aimed at identifying key bioactive factors, reconstituting them into a synthetic cocktail (SYNT), and evaluating its efficacy in TBI models. Metabolomic profiling identified three prostaglandins and kynurenine, which are used to create SYNT. The SYNT formulation reduced cell death, neuronal damage, and induced protective gene expression changes associated with neuronal protection and microglia modulation toward beneficial phenotype after TBI in vitro. In vivo, SYNT conferred similar long‐term functional benefits as CM, improving sensorimotor function up to 6 months and memory preservation at 4 months compared to saline‐treated animals, though only CM reduced contusion volume at 5 months. Both treatments modulated neuroinflammation, evidenced by reduced microglial activation and astrogliosis in the pericontusional tissue at 6 months. These findings demonstrate the neuroprotective effects of MSC‐secretome treatment in TBI and highlight prostaglandins and kynurenine as key mediators of this response. The findings lay the groundwork for developing a standardized, cell‐free therapeutic strategy for TBI based on MSC derivatives.
- 19 June 2025
- Published by Wiley in Advanced Science
- Vol. 12 (29) , e15508
Open AccessMesenchymal Stromal Cell Secretome and Its Key Bioactive Metabolites Induce Long‐Term Neuroprotection After Traumatic Brain Injury in Mice
The severe and long‐term consequences of traumatic brain injury (TBI) highlight the urgent need for effective neuroprotective therapies. Mesenchymal stromal cells (MSCs) show promise in TBI treatment through their secretome (conditioned media, CM). A low‐molecular‐weight (<700 Da) CM fraction with neuroprotective effects comparable to total CM after acute brain injury in vitro is previously identified. Here, it is aimed at identifying key bioactive factors, reconstituting them into a synthetic cocktail (SYNT), and evaluating its efficacy in TBI models. Metabolomic profiling identified three prostaglandins and kynurenine, which are used to create SYNT. The SYNT formulation reduced cell death, neuronal damage, and induced protective gene expression changes associated with neuronal protection and microglia modulation toward beneficial phenotype after TBI in vitro. In vivo, SYNT conferred similar long‐term functional benefits as CM, improving sensorimotor function up to 6 months and memory preservation at 4 months compared to saline‐treated animals, though only CM reduced contusion volume at 5 months. Both treatments modulated neuroinflammation, evidenced by reduced microglial activation and astrogliosis in the pericontusional tissue at 6 months. These findings demonstrate the neuroprotective effects of MSC‐secretome treatment in TBI and highlight prostaglandins and kynurenine as key mediators of this response. The findings lay the groundwork for developing a standardized, cell‐free therapeutic strategy for TBI based on MSC derivatives.